Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2019

View Archived Issues

BLU-5937: P2X3 homotrimeric receptor antagonist with improved taste safety profile for cough

Long-term data presented from FORWARD-2 study of ALKS-5461

NRD.E1 demonstrates promising safety and efficacy in proof-of-concept study

Results from first portion of phase I study of PRN-1371 in patients with solid tumors

Location, location, location: Looking between the lines leads to neurofibromatosis insight

A novel antagonistic CD73 antibody for cancer immunotherapy presented

Fruit fly avatars identify drug sensitivity

Flu virus makes bacteria stick around

NI-956, a new prodrug inhibitor of aminopeptidase A, shows promise for hypertension treatment

Discovery of a broad-spectrum human antibody to influenza A recognizing a new site of vulnerability

FDA approves Zolgensma for spinal muscular atrophy

MIDRIXneo, a personalized vaccine as adjuvant therapy for immune checkpoint blockade

Jakafi approved by FDA for steroid-refractory acute GvHD

Aclaris Therapeutics patents JAK1 and JAK3 inhibitors

ORIC Pharmaceuticals presents CD73 inhibitors

FDA approves Piqray for HR+/HER2-, PIK3CA-mutated advanced breast cancer

Zealand Pharma describes amylin and/or calcitonin receptor agonists

Nanjing CART Medical Technologies discloses CAR T cells for hematologic cancer

Alpine Immune Sciences divulges new fusion proteins

Sensorion signs hearing loss research partnership framework agreement with Institut Pasteur

PCI Biotech begins pivotal RELEASE study of fimaChem in inoperable bile duct cancer

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

Genmab initiates phase I/IIa safety study of GEN-1046 in malignant solid tumors

OnKure begins new phase I trial of OKI-179 in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...